Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.

Watanabe T, Tanigawa T, Shiba M, Nadatani Y, Nagami Y, Sugimori S, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T.

Gut. 2014 Mar;63(3):409-14. doi: 10.1136/gutjnl-2013-304713. Epub 2013 May 22.

PMID:
23697473
2.

Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage.

Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T.

Dig Liver Dis. 2013 May;45(5):390-5. doi: 10.1016/j.dld.2012.12.005. Epub 2013 Jan 18.

PMID:
23333664
3.

Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users.

Muraki M, Fujiwara Y, Machida H, Okazaki H, Sogawa M, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Tominaga K, Watanabe T, Arakawa T.

Scand J Gastroenterol. 2014 Mar;49(3):267-73. doi: 10.3109/00365521.2014.880182. Epub 2014 Jan 13.

PMID:
24417613
4.

Visible small-intestinal mucosal injury in chronic NSAID users.

Graham DY, Opekun AR, Willingham FF, Qureshi WA.

Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9.

PMID:
15645405
5.

Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs.

Sugimori S, Watanabe T, Tabuchi M, Kameda N, Machida H, Okazaki H, Tanigawa T, Yamagami H, Shiba M, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Koike T, Higuchi K, Arakawa T.

Digestion. 2008;78(4):208-13. doi: 10.1159/000190403. Epub 2009 Jan 13.

PMID:
19142000
6.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
7.

Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.

Brown RA, Spina D, Butt S, Summers GD.

Clin Rheumatol. 2012 Mar;31(3):455-61. doi: 10.1007/s10067-011-1863-6. Epub 2011 Oct 19.

PMID:
22009196
8.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

9.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.

Söderlin MK, Petersson IF, Geborek P.

Scand J Rheumatol. 2012 Feb;41(1):1-9. doi: 10.3109/03009742.2011.599073. Epub 2011 Nov 28.

PMID:
22118371
10.

Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.

Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø.

Ann Rheum Dis. 2009 Feb;68(2):249-52. doi: 10.1136/ard.2008.094490. Epub 2008 Aug 22.

PMID:
18723564
11.

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Jan;56(1):13-20.

12.

[Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China].

Wang XR, Su Y, An Y, Zhou YS, Zhang XY, Duan TJ, Zhu JX, Li XF, Wang CH, Wang LZ, Wang YF, Yang R, Wang GC, Lu X, Zhu P, Chen LN, Wang Y, Wang XY, Jin HT, Liu JT, Chen HY, Wei P, Wang JX, Liu XY, Sun L, Cui LF, Shu R, Liu BL, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Han SL, Yang XY, Li H, Huang CB, Gao M, Lai P, Li XF, Song LJ, Mu R, Li ZG.

Beijing Da Xue Xue Bao. 2012 Apr 18;44(2):182-7. Chinese.

13.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
14.

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

PMID:
17611987
15.

Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.

Inoue T, Iijima H, Arimitsu J, Hagihara K, Kawai S, Shiraishi E, Hiyama S, Mukai A, Shinzaki S, Nishida T, Ogata A, Tsujii M, Takehara T.

Digestion. 2014;89(2):124-32. doi: 10.1159/000357229. Epub 2014 Feb 7.

PMID:
24526219
16.

Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.

Hayashi M, Kojima T, Funahashi K, Kato D, Matsubara H, Shioura T, Kanayama Y, Hirano Y, Ishiguro N.

Mod Rheumatol. 2012 Jun;22(3):363-9. doi: 10.1007/s10165-011-0527-3. Epub 2011 Oct 7.

PMID:
21979824
17.
18.

Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury.

Park SC, Chun HJ, Kang CD, Sul D.

World J Gastroenterol. 2011 Nov 14;17(42):4647-53. doi: 10.3748/wjg.v17.i42.4647. Review.

19.

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.

Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.

Joint Bone Spine. 2012 Dec;79(6):591-6. doi: 10.1016/j.jbspin.2012.02.003. Epub 2012 Apr 4.

PMID:
22480748
20.

Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy.

Rácz I, Szalai M, Kovács V, Regőczi H, Kiss G, Horváth Z.

World J Gastroenterol. 2013 Feb 14;19(6):889-96. doi: 10.3748/wjg.v19.i6.889.

Items per page

Supplemental Content

Write to the Help Desk